Physician profile
Patrick Dreher
NPI 1689016214
$4,747.46
in general payments reported to CMS, 2019-2025
20 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,373 · 2022: $844 · 2023: $772 · 2024: $419 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,546.87 | 2021-2025 | Biktarvy, Descovy, Yeztugo |
| Novo Nordisk INC | $571.63 | 2021-2023 | Rybelsus, Ozempic |
| Amgen INC. | $494.83 | 2021-2025 | Otezla |
| Astrazeneca Pharmaceuticals LP | $461.58 | 2021 | |
| Janssen Pharmaceuticals, INC | $421.55 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.56 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $226.32 | 2021-2023 | |
| Lilly USA, LLC | $174.07 | 2021-2023 | Mounjaro |
| Abbvie INC. | $159.26 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $109.36 | 2023 | |
| Insulet Corporation | $60.52 | 2021 | |
| Idorsia Pharmaceuticals US INC | $45.03 | 2023 | Quviviq |
| Abbott Laboratories | $38.04 | 2021-2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.48 | 2021 | |
| Pfizer INC. | $26.27 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $23.74 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.21 | 2021 | |
| Philips North America LLC | $17.05 | 2022 | |
| Glaxosmithkline, LLC. | $16.23 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Dreher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.